POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES - UNFLAVORED powder, for solution
POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES WITH LEMO United States - English - NLM (National Library of Medicine)

polyethylene glycol 3350 and electrolytes - unflavored powder, for solution polyethylene glycol 3350 and electrolytes with lemo

strides pharma science limited - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p), sodium sulfate anhydrous (unii: 36kcs0r750) (sodium sulfate anhydrous - unii:36kcs0r750), sodium bicarbonate (unii: 8mdf5v39qo) (sodium cation - unii:lyr4m0nh37, bicarbonate ion - unii:hn1zra3q20), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), potassium chlorate (unii: h35ks68ee7) (potassium cation - unii:295o53k152, chlorate ion - unii:08z8093742) - polyethylene glycol 3350 and electrolytes for oral solution is indicated for bowel cleansing prior to colonoscopy and barium enema x-ray examination in adults polyethylene glycol 3350 and electrolytes for oral solution, is contraindicated in the following conditions: -   gastrointestinal (gi) obstruction [see warnings and precautions (5.6)] -   bowel perforation [see warnings and precautions (5.6)] -   toxic colitis or toxic megacolon -   gastric retention -   ileus -   hypersensitivity to any component of polyethylene glycol 3350 and electrolytes for oral solution [see warnings and precautions (5.8)] animal reproduction studies have not been conducted with polyethylene glycol 3350 and electrolytes for oral solution. it is also not known whether polyethylene glycol 3350 and electrolytes for oral solution, can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. polyethylene glycol 3350 and electrolytes for oral solution, should be given to a pregnant woman only if clearl

Dimethyl fumarate Mylan European Union - English - EMA (European Medicines Agency)

dimethyl fumarate mylan

mylan ireland limited - dimethyl fumarate - multiple sclerosis, relapsing-remitting - immunosuppressants - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Dimethyl fumarate Polpharma European Union - English - EMA (European Medicines Agency)

dimethyl fumarate polpharma

zaklady farmafarmaceutyczne polpharma s.aceutyczne polpharma s.a. - dimethyl fumarate - multiple sclerosis, relapsing-remitting - immunosuppressants - dimethyl fumarate polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Dimethyl fumarate Neuraxpharm European Union - English - EMA (European Medicines Agency)

dimethyl fumarate neuraxpharm

laboratorios lesvi s.l. - dimethyl fumarate - multiple sclerosis, relapsing-remitting - immunosuppressants - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Dimethyl fumarate Teva European Union - English - EMA (European Medicines Agency)

dimethyl fumarate teva

teva gmbh - dimethyl fumarate - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosuppressants - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Dimethyl fumarate Accord European Union - English - EMA (European Medicines Agency)

dimethyl fumarate accord

accord healthcare s.l.u. - dimethyl fumarate - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosuppressants - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

POLYETHYLENE GLYCOL-3350 AND ELECTROLYTES WITH FLAVOR PACK powder, for solution United States - English - NLM (National Library of Medicine)

polyethylene glycol-3350 and electrolytes with flavor pack powder, for solution

novel laboratories, inc. - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p), sodium chloride (unii: 451w47iq8x) (chloride ion - unii:q32zn48698), sodium bicarbonate (unii: 8mdf5v39qo) (sodium cation - unii:lyr4m0nh37), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152), sodium sulfate anhydrous (unii: 36kcs0r750) (sulfate ion - unii:7is9n8kpmg) - polyethylene glycol 3350 240 g in 278.26 g - peg-3350 (240 g) and electrolytes for oral solution, usp with flavor pack is indicated for bowel cleansing prior to colonoscopy or barium enema x-ray examination. peg-3350 (240 g) and electrolytes for oral solution with flavor pack is contraindicated in patients known to be hypersensitive to any of the components. peg-3350 (240 g) and electrolytes for oral solution with flavor pack is contraindicated in patients with ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis or toxic megacolon.

METHYLDOPA tablet, film coated United States - English - NLM (National Library of Medicine)

methyldopa tablet, film coated

carilion materials management - methyldopa (unii: 56lh93261y) (methyldopa anhydrous - unii:m4r0h12f6m) - methyldopa anhydrous 250 mg - hypertension. methyldopa is contraindicated in patients: - with active hepatic disease, such as acute hepatitis and active cirrhosis. - with liver disorders previously associated with methyldopa therapy (see ). warnings - with hypersensitivity to any component of this product. - on therapy with monoamine oxidase (mao) inhibitors.

POLYETHYLENE GLYCOL 3350 NF PEGYLAX- polyethylene glycol 3350 powder, for solution United States - English - NLM (National Library of Medicine)

polyethylene glycol 3350 nf pegylax- polyethylene glycol 3350 powder, for solution

martin ekwealor pharmaceuticals, inc. - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p) - polyethylene glycol 3350 17 g in 17 g - for the treatment of occasional constipation. this product should be used for 2 weeks or less as directed by a physician. polyethylene glycol 3350 nf is contraindicated in patients with known or suspected bowel obstruction and patients known to be allergic to polyethylene glycol.

DIMETHYL FUMARATE SANDOZ dimethyl fumarate 120 mg modified release capsule blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

dimethyl fumarate sandoz dimethyl fumarate 120 mg modified release capsule blister pack

sandoz pty ltd - dimethyl fumarate, quantity: 120 mg - capsule, modified release - excipient ingredients: ethanol; iron oxide black; purified water; iron oxide yellow; gelatin; propylene glycol; triethyl citrate; purified talc; strong ammonia solution; butan-1-ol; shellac; methacrylic acid - ethyl acrylate copolymer (1:1); croscarmellose sodium; methacrylic acid copolymer; isopropyl alcohol; glyceryl monostearate 40-55 per cent; colloidal anhydrous silica; brilliant blue fcf; sodium stearylfumarate; polysorbate 80; titanium dioxide - dimethyl fumarate sandoz is indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.